Market Trends of Pelvic Inflammatory Disease Therapeutics Industry
Tetracyclines Segment is Expected to Register Significant Growth in the Pelvic Inflammatory Disease Therapeutics Market During the Forecast Period
- Tetracycline, along with other drugs such as doxycycline and azithromycin, is used to treat pelvic inflammatory diseases as it works by inhibiting bacterial protein synthesis, thus preventing bacteria from multiplying and causing further infection.
- Tetracycline drugs are expected to dominate the industry during the forecast period. The lucrative growth of the segment can be attributed to the rise in the adoption of novel drugs due to proven efficiency in the treatment of bacterial infections and the rising number of clinical studies by the companies that fuel the availability of novel drugs in the market.
- Additionally, a growing number of research studies related to the safety and efficacy of tetracyclines in treating pelvic inflammatory diseases is expected to boost their adoption among the target patients, boosting segment growth.
- Various research studies were conducted to determine the safety, efficacy, and clinical utility of the three generations of tetracycline-class drugs. For instance, an article published by the Annals of Medicine in June 2022 highlighted adequate safety records and a broad spectrum of activity, making tetracycline-class antibiotics a preferred choice for treating diverse bacterial infections. In addition, the newest generation, featuring drugs like eravacycline, tigecycline, and omadacycline, effectively counteracts the most prevalent tetracycline resistance mechanisms. Thus, the high safety and efficacy of tetracycline antibiotics are anticipated to increase their adoption in the treatment of various pelvic infections, boosting segment growth.
- Similarly, the findings from the 2022 International AIDS Conference revealed that doxycycline reduced the risk of contracting chlamydia by 74% and syphilis by 77% among individuals living with HIV. Furthermore, an article published by the New England Journal of Medicine stated that among men who have sex with men (MSM) and transgender women, taking the oral antibiotic doxycycline within 72 hours of condomless sex prevented the contraction of sexually transmitted infections (STIs). Hence, the efficacy of tetracycline in reducing bacterial infections is anticipated to fuel the demand for such drugs in the market, propelling segment growth.
- Furthermore, the rising number of clinical trials conducted by companies and institutes accelerates the development of novel therapeutics for the treatment of pelvic disease, thereby bolstering segment growth. For instance, in February 2024, the National Institute of Allergy and Infectious Diseases (NIAID) conducted a Phase IV study to compare the efficacy of a three-day vs. seven-day regimen of doxycycline for the treatment of urogenital chlamydia (CT) infection among the population in the United States and Kenya.
- Therefore, owing to factors such as rising clinical and research studies related to oral antibiotics, the segment is anticipated to witness significant growth during the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Hold Significant Market Share During the Forecast Period
- North America is expected to witness a significant market share during the forecast period owing to factors such as the increasing pelvic organ diseases, rising cases of sexually transmitted infections owing to the adoption of unprotected sex, rising healthcare awareness regarding infectious diseases, and the growing aging population. In addition, increasing government initiatives and new product launches by companies are expected to boost the market’s growth during the forecast period.
- The market is poised for growth, driven by a surge in sexually transmitted infections, a consequence of increasing instances of unprotected sex. For instance, as per a Sexually Transmitted Infections Monthly Surveillance Report published in May 2024, about 503 cases of chlamydia (50.2 cases per 100,000 population), 175 cases of gonorrhea (17.5 cases per 100,000), and 11 cases of early syphilis (1.1 cases per 100,000) were diagnosed among St. Louis County residents, United States. In addition, St. Louis County residents were diagnosed with 175 Neisseria gonorrhoeae infections in May 2024, resulting in an incidence rate of 17.5 cases per 100,000 residents.
- Similarly, in April 2023, a report published by the Centers for Disease Control and Prevention (CDC) stated that STDs remain a significant public health concern in the United States. Thus, the burden of STDs leads to the development of infection and inflammation in the pelvic organs, further raising the risk of developing PID. This is expected to boost the demand for PID therapeutics across the region, bolstering market growth.
- Furthermore, as governments increasingly set guidelines for the use of doxycycline antibiotics, particularly against bacterial infections like STDs, the drug's adoption is expected to surge among the target population, bolstering market expansion. For instance, in November 2023, the BC Centre for Excellence in HIV/AIDS (BC-CfE), Canada, launched a new doxycycline initiative for the prevention of sexually transmitted infections, including syphilis, gonorrhea, and chlamydia. Such initiatives enable the access people in BC to get the treatment they need to protect themselves against bacterial sexually transmitted infections (b-STIs), specifically syphilis, gonorrhea, and chlamydia.
- Similarly, in October 2023, the US Centers for Disease Control and Prevention (CDC) proposed guidelines for utilizing the antibiotic doxycycline as post-exposure prophylaxis against bacterial sexually transmitted infections (STIs). The guidelines recommend that individuals, specifically gay, bisexual, and other men who have sex with men, along with transgender women, who have had gonorrhea, chlamydia, or syphilis at least once in the past year, should consider a single 200 mg oral dose of doxycycline within 72 hours of engaging in oral, anal, or vaginal sex.
- Moreover, the rising number of new drug launches and approvals fuel the availability of novel therapeutics for the treatment of pelvic inflammatory diseases in the market. For instance, in February 2024, Enmetazobactam received a new drug approval (NDA) from the Food and Drug Administration for use in patients aged 18 years or older with complicated urinary tract infections (cUTIs) such as pyelonephritis.
- Similarly, in June 2023, the US Food and Drug Administration granted a fast-track designation to GSK PLC for its Neisseria gonorrhoeae investigational vaccine (NgG), which is in an ongoing Phase II trial and aims to demonstrate proof of concept by assessing the efficacy of the NgG vaccine in healthy adults aged 18 to 50 years, considered at risk of gonorrhea.
- In January 2022, the US Food and Drug Administration accepted a Priority Review for the new drug application for tebipenem HBr (tebipenem pivoxil hydrobromide) by Spero Therapeutics for treating adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms.
- Therefore, owing to the high burden of chlamydia and gonorrhea infections among the population, new drug launches and approvals, and growing government initiatives, the market studied is expected to grow during the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
